Original articleThe impact of high-risk patients on the results of clinical trials☆
References (67)
Generalizing the results of randomized clinical trials
Control Clin Trials
(1994)Can overall results of clinical trials be applied to all patients?
Lancet
(1995)- et al.
Staging system for clinical AIDS patients: Royal Free/Chelsea and Westminster Hospital Collaborative Group
Lancet
(1995) - et al.
Concorde trial of immediate versus deferred zidovudine
Lancet
(1994) - et al.
Beneficial effects of intravenous immunoglobulins in AIDS
Lancet
(1992) - et al.
Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
Lancet
(1992) Mega-trials and management of acute myocardial infarction
Lancet
(1995)Randomized trials of magnesium in acute myocardial infarction: Big numbers do not tell the whole story
Am J Cardiol
(1995)- et al.
Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studies
Lancet
(1996) - et al.
An experimental model examining the role of magnesium in the therapy of acute myocardial infarction
Am J Cardiol
(1995)
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: Results from the GUSTO trial
Lancet
(1997)
Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
Lancet
(1994)
Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: A mathematical model
AIDS
(1996)
Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
Ann Intern Med
(1995)
Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
Science
(1996)
Viral counts count in HIV infection
Science
(1996)
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
Nature Med
(1996)
Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
Science
(1996)
Factors affecting survival in patients with the acquired immunodeficiency syndrome
AIDS
(1996)
Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population
Lancet
(1996)
Immunodeficiency and the risk of death in HIV infection
JAMA
(1992)
Survival trends for patients with AIDS
JAMA
(1990)
Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir
Delta: A randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
Lancet
(1996)
A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
N Engl J Med
(1996)
CAESAR: Confirmation of the clinical benefit of 3TC in HIV-1 disease: Preliminary results
Saquinavir vs. zalcitabine vs. combination as treatment for advanced HIV infection in patients discontinuing/unable to take zidovudine
Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
Lancet
(1994)
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease
Ann Intern Med
(1995)
Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: A meta-analysis
Ann Intern Med
(1995)
A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS
J Infect Dis
(1993)
Clarithromycin therapy for bacteremic Mycobacterium avium complex: A randomized, double-blind, dose-ranging study in patients with AIDS: AIDS Clinical Trials Group Protocol 157 Study Team
Ann Intern Med
(1994)
Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection
AIDS
(1997)
Cited by (0)
- ☆
This work was supported in part by grants T32 A107389 from the National Institute of Allergy and Infectious Diseases (Dr. Ioannidis) and R01 HS07782 from the Agency for Health Care Policy and Research (Dr. Lau), United States Public Health Service.
- 1
Current affiliation for Dr. Ioannidis: HIV Research Branch, Therapeutics Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Copyright © 1997 Published by Elsevier Inc.